[go: up one dir, main page]

US20070264296A1 - Biofilm extracellular polysachharide solvating system - Google Patents

Biofilm extracellular polysachharide solvating system Download PDF

Info

Publication number
US20070264296A1
US20070264296A1 US11/431,495 US43149506A US2007264296A1 US 20070264296 A1 US20070264296 A1 US 20070264296A1 US 43149506 A US43149506 A US 43149506A US 2007264296 A1 US2007264296 A1 US 2007264296A1
Authority
US
United States
Prior art keywords
acid
biofilms
removal
solvating
breakdown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/431,495
Inventor
Matthew Myntti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Xomed LLC
Original Assignee
Medtronic Xomed LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Xomed LLC filed Critical Medtronic Xomed LLC
Priority to US11/431,495 priority Critical patent/US20070264296A1/en
Assigned to MEDTRONIC XOMED, INC. reassignment MEDTRONIC XOMED, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MYNTTI, MATTHEW F.
Priority to US11/739,528 priority patent/US7959943B2/en
Priority to US11/739,480 priority patent/US7993675B2/en
Priority to US11/739,508 priority patent/US7976873B2/en
Priority to KR1020087027422A priority patent/KR101453011B1/en
Priority to JP2009510146A priority patent/JP5912218B2/en
Priority to AU2007249413A priority patent/AU2007249413B2/en
Priority to CA2651646A priority patent/CA2651646C/en
Priority to PCT/US2007/068477 priority patent/WO2007134055A1/en
Priority to ES07762011.0T priority patent/ES2650974T3/en
Priority to CN201510116539.8A priority patent/CN104815328A/en
Priority to EP07762011.0A priority patent/EP2029232B1/en
Priority to CNA2007800167949A priority patent/CN101443079A/en
Publication of US20070264296A1 publication Critical patent/US20070264296A1/en
Priority to US12/490,246 priority patent/US7976875B2/en
Priority to US13/182,275 priority patent/US8691288B2/en
Priority to JP2014173789A priority patent/JP2014240419A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates generally to the field of biofilm removal and more specifically to a solvating system for the solvation and removal of biofilms.
  • the solvating system may be used on a variety of affected surfaces, including human or animal tissue, medical devices, water systems, and the like.
  • the solvating system is especially beneficial for use on human tissue to remove biofilms which cause chronic conditions such as rhinosinusitis.
  • Biofilms are formed by bacteria in aqueous environments, which interact with the surfaces to which they are exposed to form surface colonies and films which continue to adhere to the surfaces and grow. More specifically, the bacteria produce extensive exopolysaccharide or extracellularpolysaccharide polymers (EPS or ECPS) that keep them attached to the surfaces and form living films thereon, frequently called “biofilms”. These biofilms can be formed on a variety of surfaces, including human tissues, medical devices, dental office equipment, counters, pipes and the like. Biofilms coat the surface and become a living colony for the continued proliferation of microorganisms, and protection of the microorganisms from removal and from conditions which might destroy the microorganisms. Biofilms are much more difficult to remove than bacteria in the plaktonic state, and the bacterial contamination of the biofilms from surfaces or tissue are thus much more difficult to eliminate. Biofilms in this state are extremely resistant to many antibiotics and biocides.
  • EPS or ECPS extracellularpolysaccharide polymers
  • biofilms When present on human tissues, biofilms can cause chronic conditions from which many persons today suffer. Such conditions include rhinosinusitis, where biofilms are attached within the nasal passages and sinuses, infiltrating and protecting the underlying pathogenic bacteria and preventing them from being dislodged from there surfaces, and immune system disorder symptoms where biofilms have coated bodily tissues and surfaces such as joints or nerves in a manner which impairs the normal function thereof. Additionally, enclosure of implants or surgical appliances with biofilms may lessen their effectiveness.
  • solvating system for removing biofilms from human tissues which would meet biocompatibility requirements for contact with human tissue, and yet be effective in removal of such biofilms from tissues and bodily orifice linings such as nasal orifices, sinuses, oral tissues, for removal from implants or other appliances attached to bodily tissues and the like.
  • Such desirable solvating systems would preferably be effective in small dosages for short periods of application. It would also be desirable for such solvating system to be further useful to dislodge biofilms attached to non-tissue surfaces in environmental locations such as medical devices and water systems, dental equipment and the like.
  • a solvating system comprising an alkali, metallic, or metal ion sequestering agent and a solvent or surfactant is surprisingly effective in removal of biofilms such as polysaccharides from human tissue while being gentle enough for application directly onto such tissues.
  • the invention provides a solvating system for the breakdown and/or removal of biofilm matrices from human tissue surfaces and nonhuman surfaces.
  • the invention provides an aqueous solvating system for the breakdown of the biofilm's extracellular polysaccharide matrix, and consequent detachment/removal of biofilms from the surface to which it is attached or adhered.
  • the solvating system of the invention comprises a metal ion sequestering agent and a solvating agent for the extracellular polysaccharide matrix selected from a solvent or a surfactant.
  • the invention includes an aqueous solvating system comprising water or saline, a metal ion sequestering agent and a solvating agent selected from the group consisting of a solvent and a surfactant.
  • the solvating system of the invention comprises metal ion sequestering agent selected from the group consisting of a mild acid having a molarity of at least about 0.05 molar.
  • the metal ion sequestering agent is a mild acid having a molarity of at least about 0.05 molar wherein the metal ion is selected from alkali metals, alkaline earth metals, and iron.
  • the solvating system comprises a solvating agent for the extracellular polysaccharide matrix selected from the group consisting of anionic surfactants, nonionic surfactants, cationic surfactants and zwitterionic surfactants.
  • the invention also provides a method of use for the solvating system comprising delivery to the affected location by power spray or lavage.
  • the term “sequestering agent” means a chemical that will combine with another material, especially a metal ion, to prevent the material from coming out of solution.
  • metal ion sequestering agent means a sequestering agent that will combine with metal ions such as iron, alkali metals, alkaline earth metals, and the like to keep the metals in solution.
  • metal ions such as iron, alkali metals, alkaline earth metals, and the like to keep the metals in solution.
  • the alkaline earth metals are beryllium, magnesium, calcium, strontium, barium, and radium.
  • Alkali metals include sodium, potassium, rubidium, cesium, and francium.
  • attachment means that the biofilm is established on the surface which it coats or covers, and that the biofilm has some resistance to removal from the surface, whether the surface is living tissue or a nonliving surface. As the nature of this relationship is complex and poorly understood, no particular method of adherence or attachment is intended by such usage.
  • solvating means to form a solution consisting of the solvent and the solvate.
  • the term “removal of biofilms” means that at least a significant amount of the biofilm present on a surface is placed into suspension and no longer resides on the surface.
  • the invention provides an aqueous solvating system for the breakdown of the biofilm's extracellular polysaccharide matrix, and consequent detachment or removal of biofilms from the surface to which it is attached or adhered.
  • the solvating system of the invention comprises a metal ion sequestering agent and a solvating agent for the extracellular polysaccharide matrix selected from a solvent or a surfactant.
  • the invention is biocompatible, and may be used directly on human tissue as well as other non-living surfaces. It is advantageous in that it contains no biocides which could be potentially harmful to human tissues.
  • the solvating system invention is low viscosity which makes for easy delivery to the desired surface by means of lavage, misting, spray application, mopping, administering in droplets, and also easy removal by subsequently flushing, rinsing, and/or draining from orifices such as nasal passages or from other surfaces.
  • the solvating system has a pH of from greater than about 5 to about 8.5.
  • the sequestering agent is an metal ion sequestering agent, generally a mild acid of high molarity.
  • Useful acids include citric acid, mandelic acid, 2-ketoglutaric acid, acetic acid, iminodiacetic acid, mucic acid, clycolic acid, fumaric acid, lactic acid, aspartic acid, phosphoric acid, pyruvic acid, chloroacetic acid, oxalic acid, oxamic acid, malic acid, dichloroacetic acid, phenylacetic acid, benzylic acid, maleic acid, succinic acid, chloromandelic acid, glutamic acid, nitrilotriacetic acid, boric acid, adipic acid, formic acid, glucuronic acid, salicylic acid, benzoic acid, benzoyl acid, formic acid, pthalic acid, ketopimelic acid, and hydrochloric acid.
  • Applicable metal ions which may be sequestered include alkali metals, alkaline earth metals, iron, and the like.
  • the metal ion sequestering agent is an alkaline earth metal or alkali metal sequestering agent.
  • the sequestering agent generally has a molarity of at least about 0.05 molar, preferably from about 0.05 to about 0.35 molar.
  • the solvating system further includes a solvating agent selected from a surfactant or solvent.
  • a solvating agent selected from a surfactant or solvent.
  • Useful solvating agents include surfactants such as alkyl sulfates, alkyl sulfonates and aryl sulfonates.
  • the surfactant is generally present in a strength of from about 0.001 to about 0.69 molar, preferably from about 0.025 to about 0.130 molar, and in an amount of from about 0.5% to about 20% of the weight of the solution.
  • the solvating agent may be selected from various surfactants, such as anionic surfactants, nonionic surfactants, cationic surfactants and zwitterionic surfactants.
  • useful anionic surfactants include but are not limited to, sodium chenodeoxycholate, N-lauroylsarcosine sodium salt, lithium dodecyl sulfate, 1-octanesulfonic acid sodium salt, sodium cholate hydrate, sodium deoxycholate, sodium dodecyl sulfate, and sodium glycodeoxycholate.
  • Useful cationic surfactants include but are not limited to hexadecylpyridinium chloride monohydrate, and hexadecyltrimethylammonium bromide.
  • Useful nonionic surfactants include but are not limited to polyoxyethyleneglycol dodecyl ether, N-decanoyl-N-methylglucamine, Digitonin, n-dodecyl B-D-maltoside, octyl B-D-glucopyranoside, octylphenol ethoxylate, polyoxyethylene (8) isooctyl phenyl ether, polyoxyethylene sorbitan monolaurate, and polyoxyethylene (20) sorbitan monooleate.
  • Useful zwitterionic surfactant include but are not limited to 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propane sulfonate, 3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate, 3-(decyldimethlammonio)propanesulfonate inner salt, and N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate.
  • the surfactant is sodium lauryl sulfate.
  • the metal ion sequestering material removes the ion which bridges the extracellular polysaccharide matrix and binds the polymer chains together.
  • the solvating agent then first surrounds the unbound polymers and suspends them, breaking down the matrix, and subsequently solvates the unbound polymers, bringing them into solution where they can be easily flushed from the tissues or surfaces with the aqueous solvating solution.
  • the solvating system of the invention may further include medicaments such as antibiotics, which will be much more effective against the microorganisms present after the extracellular polysaccharide matrix has been broken down into unbound polymers, suspended and/or solvated.
  • the solvating system may further include a buffer in order to provide a solution at the proper pH for contacting human tissue.
  • the buffer may comprise up to about 25% of the active ingredients of the solution.
  • Useful buffers include, but are not limited to potassium chloride, glycine, potassium hydrogen phthalate, sodium acetate, potassium hydrogen phthalate, barbitone sodium, and sodium citrate.
  • the solvating system of the invention may include further pharmaceutical agents in appropriate dosages such as analgesics, steroids, and the like.
  • the solvating system may further include flavoring agents and sweetening agents including but not limited to, oil of peppermint, spearmint, wintergreen, clove, eucalyptus, cinnamon, lemon, lime and orange, cherry, sucrose, lactose, maltose, sorbitol, xylitol, sodium cyclamate, saccharine, and the like.
  • flavoring agents and sweetening agents including but not limited to, oil of peppermint, spearmint, wintergreen, clove, eucalyptus, cinnamon, lemon, lime and orange, cherry, sucrose, lactose, maltose, sorbitol, xylitol, sodium cyclamate, saccharine, and the like.
  • Additional adjuvants may include antioxidants, buffering agents, coloring agents, and the like, in amounts that will not substantially interfere with the solvation of the extracellular polysaccharide and removal of the significant amounts of the biofilm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The invention provides a solvating system for the removal of biofilms which solvates the extracellular polysaccharide matrix holding it to a surface. The aqueous solvating system comprises water, a metal ion sequestering agent, and a solvating agent for an extracellular polysaccharide matrix, which is gentle enough to be used directly on human tissues, but which may also be used on hard or soft non-tissue surfaces to breakdown, and/or remove biofilms.

Description

    THE FIELD OF THE INVENTION
  • The present invention relates generally to the field of biofilm removal and more specifically to a solvating system for the solvation and removal of biofilms. The solvating system may be used on a variety of affected surfaces, including human or animal tissue, medical devices, water systems, and the like. The solvating system is especially beneficial for use on human tissue to remove biofilms which cause chronic conditions such as rhinosinusitis.
    • BACKGROUND OF THE INVENTION
  • Biofilms are formed by bacteria in aqueous environments, which interact with the surfaces to which they are exposed to form surface colonies and films which continue to adhere to the surfaces and grow. More specifically, the bacteria produce extensive exopolysaccharide or extracellularpolysaccharide polymers (EPS or ECPS) that keep them attached to the surfaces and form living films thereon, frequently called “biofilms”. These biofilms can be formed on a variety of surfaces, including human tissues, medical devices, dental office equipment, counters, pipes and the like. Biofilms coat the surface and become a living colony for the continued proliferation of microorganisms, and protection of the microorganisms from removal and from conditions which might destroy the microorganisms. Biofilms are much more difficult to remove than bacteria in the plaktonic state, and the bacterial contamination of the biofilms from surfaces or tissue are thus much more difficult to eliminate. Biofilms in this state are extremely resistant to many antibiotics and biocides.
  • When present on human tissues, biofilms can cause chronic conditions from which many persons today suffer. Such conditions include rhinosinusitis, where biofilms are attached within the nasal passages and sinuses, infiltrating and protecting the underlying pathogenic bacteria and preventing them from being dislodged from there surfaces, and immune system disorder symptoms where biofilms have coated bodily tissues and surfaces such as joints or nerves in a manner which impairs the normal function thereof. Additionally, enclosure of implants or surgical appliances with biofilms may lessen their effectiveness.
  • Previous strategies for removal of biofilms have focused on both removal and destruction of bacteriums in the biofilm. Products for such cleansing, such as biocides, disinfectants and the like for use in such areas may be caustic and employ agents that can damage human skin, and especially non-dermal human tissues upon contact and therefore cannot be used to remove biofilms from human orifices and tissues. Methods of cleaning and disinfecting such surfaces effectively for biofilms may also involve large dosages, and long periods of contact with the surface, e.g., soaking biofilm contaminated surfaces for 12-24 hours, which is impractical for preoperative and postoperative situations and for many surfaces and devices as well as being impossible for use on or with most contaminated human tissues.
  • Methods of removal of biofilms from human tissues such as sinuses to flush them from the system have included mechanical debridement of the tissues and/or surgical opening of sinuses to allow for drying and subsequent removal of the biofilm. Such methods damage the tissues and require healing periods, and further present opportunities for new bacteria to contact the surfaces and cause infections and new placement of biofilms. Antibiotics have also been attempted but, while they are effective against plaktonic bacteria, they have been only marginally effective against biofilms, and then only when administered in large dosages, which may be otherwise undesirable for the patient or living tissues.
  • It would be desirable to have a solvating system for removing biofilms from human tissues which would meet biocompatibility requirements for contact with human tissue, and yet be effective in removal of such biofilms from tissues and bodily orifice linings such as nasal orifices, sinuses, oral tissues, for removal from implants or other appliances attached to bodily tissues and the like. Such desirable solvating systems would preferably be effective in small dosages for short periods of application. It would also be desirable for such solvating system to be further useful to dislodge biofilms attached to non-tissue surfaces in environmental locations such as medical devices and water systems, dental equipment and the like.
  • It has now been discovered that a solvating system comprising an alkali, metallic, or metal ion sequestering agent and a solvent or surfactant is surprisingly effective in removal of biofilms such as polysaccharides from human tissue while being gentle enough for application directly onto such tissues.
    • SUMMARY OF THE INVENTION
  • The invention provides a solvating system for the breakdown and/or removal of biofilm matrices from human tissue surfaces and nonhuman surfaces.
  • More specifically, the invention provides an aqueous solvating system for the breakdown of the biofilm's extracellular polysaccharide matrix, and consequent detachment/removal of biofilms from the surface to which it is attached or adhered. The solvating system of the invention comprises a metal ion sequestering agent and a solvating agent for the extracellular polysaccharide matrix selected from a solvent or a surfactant.
  • In one embodiment, the invention includes an aqueous solvating system comprising water or saline, a metal ion sequestering agent and a solvating agent selected from the group consisting of a solvent and a surfactant.
  • In another embodiment, the solvating system of the invention comprises metal ion sequestering agent selected from the group consisting of a mild acid having a molarity of at least about 0.05 molar.
  • In one embodiment, the metal ion sequestering agent is a mild acid having a molarity of at least about 0.05 molar wherein the metal ion is selected from alkali metals, alkaline earth metals, and iron.
  • In another embodiment, the solvating system comprises a solvating agent for the extracellular polysaccharide matrix selected from the group consisting of anionic surfactants, nonionic surfactants, cationic surfactants and zwitterionic surfactants.
  • The invention also provides a method of use for the solvating system comprising delivery to the affected location by power spray or lavage.
  • These terms when used herein have the following meanings.
  • 1. The term “sequestering agent” means a chemical that will combine with another material, especially a metal ion, to prevent the material from coming out of solution.
  • 2. The term “metal ion sequestering agent” means a sequestering agent that will combine with metal ions such as iron, alkali metals, alkaline earth metals, and the like to keep the metals in solution. In order of increasing atomic number the alkaline earth metals are beryllium, magnesium, calcium, strontium, barium, and radium. Alkali metals include sodium, potassium, rubidium, cesium, and francium.
  • 3. The terms “attached” and “adhered” as used herein means that the biofilm is established on the surface which it coats or covers, and that the biofilm has some resistance to removal from the surface, whether the surface is living tissue or a nonliving surface. As the nature of this relationship is complex and poorly understood, no particular method of adherence or attachment is intended by such usage.
  • 4. The term “solvating” means to form a solution consisting of the solvent and the solvate.
  • 5. The term “removal of biofilms” means that at least a significant amount of the biofilm present on a surface is placed into suspension and no longer resides on the surface.
  • All weights, amounts and ratios herein are by weight, unless otherwise specifically noted.
    • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The following detailed description describes certain embodiments and is not to be taken in a limiting sense. The scope of the present invention is defined by the appended claims.
  • The invention provides an aqueous solvating system for the breakdown of the biofilm's extracellular polysaccharide matrix, and consequent detachment or removal of biofilms from the surface to which it is attached or adhered. The solvating system of the invention comprises a metal ion sequestering agent and a solvating agent for the extracellular polysaccharide matrix selected from a solvent or a surfactant.
  • The invention is biocompatible, and may be used directly on human tissue as well as other non-living surfaces. It is advantageous in that it contains no biocides which could be potentially harmful to human tissues.
  • Another advantage of the solvating system invention is that it is low viscosity which makes for easy delivery to the desired surface by means of lavage, misting, spray application, mopping, administering in droplets, and also easy removal by subsequently flushing, rinsing, and/or draining from orifices such as nasal passages or from other surfaces. In one embodiment, the solvating system has a pH of from greater than about 5 to about 8.5.
  • The sequestering agent is an metal ion sequestering agent, generally a mild acid of high molarity. Useful acids include citric acid, mandelic acid, 2-ketoglutaric acid, acetic acid, iminodiacetic acid, mucic acid, clycolic acid, fumaric acid, lactic acid, aspartic acid, phosphoric acid, pyruvic acid, chloroacetic acid, oxalic acid, oxamic acid, malic acid, dichloroacetic acid, phenylacetic acid, benzylic acid, maleic acid, succinic acid, chloromandelic acid, glutamic acid, nitrilotriacetic acid, boric acid, adipic acid, formic acid, glucuronic acid, salicylic acid, benzoic acid, benzoyl acid, formic acid, pthalic acid, ketopimelic acid, and hydrochloric acid.
  • Applicable metal ions which may be sequestered include alkali metals, alkaline earth metals, iron, and the like. In one embodiment the metal ion sequestering agent is an alkaline earth metal or alkali metal sequestering agent. The sequestering agent generally has a molarity of at least about 0.05 molar, preferably from about 0.05 to about 0.35 molar.
  • The solvating system further includes a solvating agent selected from a surfactant or solvent. Useful solvating agents include surfactants such as alkyl sulfates, alkyl sulfonates and aryl sulfonates. The surfactant is generally present in a strength of from about 0.001 to about 0.69 molar, preferably from about 0.025 to about 0.130 molar, and in an amount of from about 0.5% to about 20% of the weight of the solution.
  • The solvating agent may be selected from various surfactants, such as anionic surfactants, nonionic surfactants, cationic surfactants and zwitterionic surfactants. Useful anionic surfactants include but are not limited to, sodium chenodeoxycholate, N-lauroylsarcosine sodium salt, lithium dodecyl sulfate, 1-octanesulfonic acid sodium salt, sodium cholate hydrate, sodium deoxycholate, sodium dodecyl sulfate, and sodium glycodeoxycholate. Useful cationic surfactants include but are not limited to hexadecylpyridinium chloride monohydrate, and hexadecyltrimethylammonium bromide. Useful nonionic surfactants include but are not limited to polyoxyethyleneglycol dodecyl ether, N-decanoyl-N-methylglucamine, Digitonin, n-dodecyl B-D-maltoside, octyl B-D-glucopyranoside, octylphenol ethoxylate, polyoxyethylene (8) isooctyl phenyl ether, polyoxyethylene sorbitan monolaurate, and polyoxyethylene (20) sorbitan monooleate. Useful zwitterionic surfactant include but are not limited to 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propane sulfonate, 3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate, 3-(decyldimethlammonio)propanesulfonate inner salt, and N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate. In one embodiment, the surfactant is sodium lauryl sulfate.
  • While not wishing to be bound by theory, it is believed that the metal ion sequestering material removes the ion which bridges the extracellular polysaccharide matrix and binds the polymer chains together. The solvating agent then first surrounds the unbound polymers and suspends them, breaking down the matrix, and subsequently solvates the unbound polymers, bringing them into solution where they can be easily flushed from the tissues or surfaces with the aqueous solvating solution.
  • Where desirable to both remove the biofilm and destroy the microorganisms contained therein, the solvating system of the invention may further include medicaments such as antibiotics, which will be much more effective against the microorganisms present after the extracellular polysaccharide matrix has been broken down into unbound polymers, suspended and/or solvated.
  • The solvating system may further include a buffer in order to provide a solution at the proper pH for contacting human tissue. Where desirable, the buffer may comprise up to about 25% of the active ingredients of the solution. Useful buffers include, but are not limited to potassium chloride, glycine, potassium hydrogen phthalate, sodium acetate, potassium hydrogen phthalate, barbitone sodium, and sodium citrate.
  • Where treatment of tissues is also desirable, the solvating system of the invention may include further pharmaceutical agents in appropriate dosages such as analgesics, steroids, and the like.
  • For comfort and ease of use in human patients, the solvating system may further include flavoring agents and sweetening agents including but not limited to, oil of peppermint, spearmint, wintergreen, clove, eucalyptus, cinnamon, lemon, lime and orange, cherry, sucrose, lactose, maltose, sorbitol, xylitol, sodium cyclamate, saccharine, and the like.
  • Additional adjuvants may include antioxidants, buffering agents, coloring agents, and the like, in amounts that will not substantially interfere with the solvation of the extracellular polysaccharide and removal of the significant amounts of the biofilm.
  • Although specific embodiments have been illustrated and described herein for purposes of description of the preferred embodiment, it will be appreciated by those of ordinary skill in the art that a wide variety of alternate and/or equivalent implementations calculated to achieve the same purposes may be substituted for the specific embodiments shown and described without departing from the scope of the present invention. Those with skill in the chemical, mechanical, electro-mechanical, electrical, pharmacological and computer arts will readily appreciate that the present invention may be implemented in a very wide variety of embodiments. This application is intended to cover any adaptations or variations of the preferred embodiments discussed herein. Therefore, it is manifestly intended that this invention be limited only by the claims and the equivalents thereof.

Claims (21)

1. A solvating system for the breakdown of biofilm matrices, removal of biofilms from a surface or contained system or both, said system comprising a solution of water, an metal ion sequestering agent, and a solvating agent for an extracellular polysaccharide matrix.
2. An aqueous solvating system for the breakdown of biofilm matrices, removal of biofilms or both according to claim 1 wherein said metal ion sequestering agent is a mild acid having a molarity of at least about 0.05 molar.
3. An aqueous solvating system for breakdown of biofilm matrices, removal of biofilms or both according to claim 2 wherein said sequestering agent is selected from the group consisting of citric acid, mandelic acid, 2-ketoglutaric acid, acetic acid, iminodiacetic acid, mucic acid, clycolic acid, fumaric acid, lactic acid, aspartic acid, phosphoric acid, pyruvic acid, chloroacetic acid, oxalic acid, oxamic acid, malic acid, dichloroacetic acid, phenylacetic acid, benzylic acid, maleic acid, succinic acid, chloromandelic acid, glutamic acid, nitrilotriacetic acid, boric acid, adipic acid, formic acid, glucuronic acid, salicylic acid, benzoic acid, benzoyl acid, formic acid, pthalic acid, ketopimelic acid, and hydrochloric acid.
4. An aqueous solvating system for the breakdown of biofilm matrices, removal of biofilms or both according to claim 1 wherein said solvating agent is selected from the group consisting of anionic surfactants, nonionic surfactants, cationic surfactants and zwitterionic surfactants.
5. An aqueous solvating system for the breakdown of biofilm matrices, removal of biofilms or both according to claim 1 wherein said system has a pH of from greater than 5 to about 8.5.
6. An aqueous solvating system for the breakdown of biofilm matrices, removal of biofilms or both according to claim 5 wherein said solvating agent is selected from the group consisting of anionic surfactants, nonionic surfactants, cationic surfactants and zwitterionic surfactants.
7. An aqueous solvating system for the breakdown of biofilm matrices, removal of biofilms or both according to claim 5 wherein said system comprises saline.
8. A solvating system for the breakdown of biofilm matrices, removal of biofilms or both from human tissue, bone, or prosthetic systems, said system comprising an aqueous solution comprising water, a metal ion sequestering agent, and a solvating agent for an extracellular polysaccharide matrix.
9. An aqueous solvating system for breakdown of biofilm matrices, removal of biofilms or both from human tissue, bone, or prosthetic systems according to claim 8 wherein said metal ion sequestering agent is a mild acid having a molarity of at least about 0.05 molar.
10. A solvating system for the breakdown of biofilm matrices, removal of biofilms or both from human tissue, bone, or prosthetic systems according to claim 8 wherein said solvating agent is selected from the group consisting of anionic surfactants, nonionic surfactants, cationic surfactants and zwitterionic surfactants.
11. A solvating system for the breakdown of biofilm matrices, removal of biofilms or both from human tissue, bone, or prosthetic systems according to claim 8 wherein said sequestering agent is selected from the group consisting of citric acid, mandelic acid, 2-ketoglutaric acid, acetic acid, iminodiacetic acid, mucic acid, clycolic acid, fumaric acid, lactic acid, aspartic acid, phosphoric acid, pyruvic acid, chloroacetic acid, oxalic acid, oxamic acid, malic acid, dichloroacetic acid, phenylacetic acid, benzylic acid, maleic acid, succinic acid, chloromandelic acid, glutamic acid, nitrilotriacetic acid, boric acid, adipic acid, formic acid, glucuronic acid, salicylic acid, benzoic acid, benzoyl acid, formic acid, pthalic acid, ketopimelic acid, and hydrocholoric acid
12. A solvating system for the removal of biofilms from human tissue, bone or prosthetic systems according to claim 11 wherein said solvating agent is selected from the group consisting of alkyl sulfates, alkyl sulfonates and aryl sulfonates.
13. A solvating system for the removal of biofilms from human tissue, bone, or prosthetic systems according to claim 8 wherein said solution has a pH of from greater than 5 to about 8.5.
14. An aqueous solvating system for the breakdown of biofilm matrices, removal of biofilms or both from human tissue, bone, or prosthetic systems according to claim 8 wherein said system comprises saline.
15. A method or procedure for use of an aqueous solvating system for the breakdown of biofilm matrices, removal of biofilms or both according to claim 1 wherein a solution of said system is applied to human tissue, bone, or prosthetic systems.
16. A method of use according to claim 15 wherein said solution is applied in the form of a spray, liquid, or gel.
17. A method of use according to claim 15 wherein said solution is applied to nasal passages and sinuses.
18. A method of use according to claim 17 wherein said solution is applied to persons with rhinosinusitius.
19. A method according to claim 18 wherein said solution is applied in the form of a spray, liquid, or gel.
20. A method of treatment of medical disorders by removal of biofilms from human tissues, bone, or prosthetic systems, said method comprising:
a. providing an aqueous solvating system solution according to claim 1,
b. applying said solution directly to said human tissue comprising said biofilm thereon,
c. removing said solution by means selected from draining, flushing, aspiration and rinsing.
21. A method of treating rhinosinusitis, otitis, and dental disorders comprising the steps of:
a. providing an aqueous solvating system solution according to claim 1,
b. applying said solution directly to a human tissue selected from nasal passages, sinuses, internal and external ears, gums, tongue, and teeth, and
c. allowing said solution to drain out of said human tissue.
US11/431,495 2006-05-10 2006-05-10 Biofilm extracellular polysachharide solvating system Abandoned US20070264296A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
US11/431,495 US20070264296A1 (en) 2006-05-10 2006-05-10 Biofilm extracellular polysachharide solvating system
US11/739,528 US7959943B2 (en) 2006-05-10 2007-04-24 Solvating system and sealant for medical use in the middle or inner ear
US11/739,480 US7993675B2 (en) 2006-05-10 2007-04-24 Solvating system and sealant for medical use in the sinuses and nasal passages
US11/739,508 US7976873B2 (en) 2006-05-10 2007-04-24 Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
CNA2007800167949A CN101443079A (en) 2006-05-10 2007-05-08 Antibacterial extracellular polysaccharide solvating system
PCT/US2007/068477 WO2007134055A1 (en) 2006-05-10 2007-05-08 Antibacterial extracellular polysaccharide solvating system
EP07762011.0A EP2029232B1 (en) 2006-05-10 2007-05-08 Antibacterial extracellular polysaccharide solvating system
AU2007249413A AU2007249413B2 (en) 2006-05-10 2007-05-08 Antibacterial extracellular polysaccharide solvating system
CA2651646A CA2651646C (en) 2006-05-10 2007-05-08 Antibacterial extracellular polysaccharide solvating system comprising a metal ion sequestering agent
KR1020087027422A KR101453011B1 (en) 2006-05-10 2007-05-08 Plasmid system for extracellular polysaccharides
ES07762011.0T ES2650974T3 (en) 2006-05-10 2007-05-08 Solvation system of antibacterial extracellular polysaccharides
CN201510116539.8A CN104815328A (en) 2006-05-10 2007-05-08 Antibacterial extracellular polysaccharide solvating system
JP2009510146A JP5912218B2 (en) 2006-05-10 2007-05-08 Antibacterial extracellular polysaccharide solvation system
US12/490,246 US7976875B2 (en) 2006-05-10 2009-06-23 Biofilm extracellular polysaccharide solvating system
US13/182,275 US8691288B2 (en) 2006-05-10 2011-07-13 Gallium-containing sealant for medical use
JP2014173789A JP2014240419A (en) 2006-05-10 2014-08-28 Anti-bacterial extracellular polysaccharide solvating system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/431,495 US20070264296A1 (en) 2006-05-10 2006-05-10 Biofilm extracellular polysachharide solvating system

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US11/739,528 Continuation-In-Part US7959943B2 (en) 2006-05-10 2007-04-24 Solvating system and sealant for medical use in the middle or inner ear
US11/739,480 Continuation-In-Part US7993675B2 (en) 2006-05-10 2007-04-24 Solvating system and sealant for medical use in the sinuses and nasal passages
US11/739,508 Continuation-In-Part US7976873B2 (en) 2006-05-10 2007-04-24 Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US12/490,246 Division US7976875B2 (en) 2006-05-10 2009-06-23 Biofilm extracellular polysaccharide solvating system

Publications (1)

Publication Number Publication Date
US20070264296A1 true US20070264296A1 (en) 2007-11-15

Family

ID=38685405

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/431,495 Abandoned US20070264296A1 (en) 2006-05-10 2006-05-10 Biofilm extracellular polysachharide solvating system
US12/490,246 Active US7976875B2 (en) 2006-05-10 2009-06-23 Biofilm extracellular polysaccharide solvating system

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/490,246 Active US7976875B2 (en) 2006-05-10 2009-06-23 Biofilm extracellular polysaccharide solvating system

Country Status (2)

Country Link
US (2) US20070264296A1 (en)
CN (1) CN101443079A (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110040226A1 (en) * 2008-04-24 2011-02-17 Medtronic, Inc. Cold ionizing radiation sterilization
US20130239991A1 (en) * 2012-01-18 2013-09-19 Nch Corporation Composition, System, and Method for Treating Water Systems
US20140309581A1 (en) * 2008-06-12 2014-10-16 Medtronic Xomed, Inc. Method for treating chronic wounds with an extracellular polymeric substance solvating system
US8940792B2 (en) 2008-10-06 2015-01-27 Next Science, Llc Antimicrobial composition and methods for using same
US9441190B2 (en) 2013-11-06 2016-09-13 Nch Corporation Composition and method for treating water systems
US9506016B2 (en) 2013-11-06 2016-11-29 Nch Corporation Composition and method for treating water systems
US9707520B2 (en) 2012-01-18 2017-07-18 Nch Corporation Composition, system, and method for treating water systems
US9827367B2 (en) 2008-04-29 2017-11-28 Medtronic Xomed, Inc. Surgical instrument, system, and method for frontal sinus irrigation
US9919939B2 (en) 2011-12-06 2018-03-20 Delta Faucet Company Ozone distribution in a faucet
US10021876B2 (en) 2013-05-02 2018-07-17 Next Science IP Holdings Pty Ltd High osmolarity antimicrobial composition containing one or more organic solvents
US10653133B2 (en) 2011-05-10 2020-05-19 Next Science IP Holdings Pty Ltd Antimicrobial solid and methods of making and using same
US10827750B2 (en) 2015-07-17 2020-11-10 Next Science IP Holdings Pty Ltd Antimicrobial composition having efficacy against endospores
WO2021059151A1 (en) 2019-09-26 2021-04-01 3M Innovative Properties Company Oral care composition with ammonium alkyl sulfonate or carbonate components for treating caries
WO2021116873A1 (en) * 2019-12-12 2021-06-17 3M Innovative Properties Company Oral care composition with n-acetyl amino acid components for treating caries
US11458214B2 (en) 2015-12-21 2022-10-04 Delta Faucet Company Fluid delivery system including a disinfectant device
JP2023512990A (en) * 2020-01-24 2023-03-30 スパイラル・セラピューティクス・インコーポレイテッド Devices, systems and methods for otology
US12059430B2 (en) 2022-09-29 2024-08-13 Adora Animal Health Corporation Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088095B2 (en) 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
EP2120561A4 (en) * 2007-02-19 2012-11-21 Plurogen Therapeutics Inc Compositions for treating biofilms and methods for using same
AU2010249574B2 (en) 2009-05-19 2015-05-14 Plurogen Therapeutics, Inc. Surface active agent compositions and methods for enhancing oxygenation, reducing bacteria and improving wound healing
US10085447B2 (en) 2011-03-11 2018-10-02 Ecolab Usa Inc. Acidic biofilm remediation
CA3115561C (en) 2011-10-08 2025-08-12 Osartis Gmbh Antimicrobial compositions and methods employing same
US9192574B2 (en) 2013-10-24 2015-11-24 Medtronic Xomed, Inc. Chitosan paste wound dressing
US9192692B2 (en) 2013-10-24 2015-11-24 Medtronic Xomed, Inc. Chitosan stenting paste
AU2016209327A1 (en) 2015-01-20 2017-08-10 Plurogen Therapeutics, Llc Compositions and methods of treating microbes
CN104971424A (en) * 2015-06-25 2015-10-14 王斌哲 Ear disease ozone treatment system
CN105770999B (en) * 2016-03-03 2019-01-29 宁夏大学 A kind of composite biological material for eliminating bacterial biofilm
CA3029601A1 (en) 2016-06-30 2018-01-04 Next Science IP Holdings Pty Ltd Antimicrobial compositions and methods employing same
US11723860B2 (en) 2017-11-19 2023-08-15 Next Science IP Holdings Pty Ltd Compositions and methods for treating intervertebral discs

Citations (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422186A (en) * 1962-08-06 1969-01-14 Purdue Frederick Co Methods for the removal of cerumen and the methods for the treatment of ear disease
US4323551A (en) * 1981-02-19 1982-04-06 The Procter & Gamble Company Mouthwash compositions
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5017229A (en) * 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5145664A (en) * 1990-06-25 1992-09-08 Thompson Mckay Pharmaceuticals, Ltd. Mouthwash
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US5229103A (en) * 1992-04-30 1993-07-20 Hydrodent Laboratories, Inc. Antiplaque mouthwash concentrate
US5246964A (en) * 1990-07-10 1993-09-21 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of inflammatory diseases with polyoxyethylenesorbitan mono-higher-fatty acid esters
US5290552A (en) * 1988-05-02 1994-03-01 Matrix Pharmaceutical, Inc./Project Hear Surgical adhesive material
US5326567A (en) * 1991-04-10 1994-07-05 Capelli Christopher C Antimicrobial compositions useful for medical applications
US5575815A (en) * 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
US5644049A (en) * 1992-07-03 1997-07-01 M.U.R.S.T. Italian Ministry For Universitites And Scientific And Technology Research Biomaterial comprising hyaluronic acid and derivatives thereof in interpenetrating polymer networks (IPN)
US5662913A (en) * 1991-04-10 1997-09-02 Capelli; Christopher C. Antimicrobial compositions useful for medical applications
US5676964A (en) * 1988-05-13 1997-10-14 Fidia, S.P.A. Crosslinked carboxy polysaccharides
US5709546A (en) * 1996-11-27 1998-01-20 Waggoner; Mark B. Water sanitizing system and process
US5895781A (en) * 1997-12-22 1999-04-20 S. C. Johnson & Son, Inc. Cleaning compositions for ceramic and porcelain surfaces and related methods
US5910420A (en) * 1996-08-16 1999-06-08 Orion-Yhtyma Oy Orion Diagnostica Method and test kit for pretreatment of object surfaces
US5925334A (en) * 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US6001870A (en) * 1996-10-01 1999-12-14 Smithkline Beecham P.L.C. Nasopharynx administration of mupirocin for prophylactic treatment of recurrent otitis media
US6013657A (en) * 1998-02-02 2000-01-11 Agis Industries Ltd. Pharmaceutical compositions containing mupirocin
US6063061A (en) * 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US6143330A (en) * 1995-11-09 2000-11-07 Aaltonen; Antti Sakari Compositions for inhibiting dental caries and/or middle ear infections and uses thereof
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6156792A (en) * 1996-10-01 2000-12-05 Smithkline Beecham Corporation Calcium mupirocin non-aqueous nasal spray for otitis media or for recurrent acute bacterial sinusitis
US6203822B1 (en) * 1996-09-03 2001-03-20 University Of Iowa Research Foundation Gallium-containing compounds for the treatment of infections caused by intracellular pathogens and pathogens causing chronic pulmonary infection
US6224857B1 (en) * 1996-10-17 2001-05-01 Fidia, S.P.A. Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics
US6248371B1 (en) * 1995-04-25 2001-06-19 Winthrop University Hospital Metal/thiol biocides
US6284804B1 (en) * 1999-09-24 2001-09-04 Alcon Universal Ltd. Topical suspension formulations containing ciprofloxacin and dexamethasone
US6375963B1 (en) * 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US6395295B1 (en) * 1997-12-24 2002-05-28 Britannia Pharmaceuticals Limited Use of surface active agent for the manufacture of a medicament for treatment of disorders of the middle ear
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US20020187918A1 (en) * 2000-02-01 2002-12-12 Reckitt Benckiser Inc. Hard surface cleaning compositions and method of removing stains
US6541460B2 (en) * 1996-08-07 2003-04-01 George D. Petito Method for use of hyaluronic acid in wound management
US20030079758A1 (en) * 1998-06-03 2003-05-01 Siegel Phyllis B. Process and composition for removing biofilm
US20030083219A1 (en) * 2000-06-05 2003-05-01 Rees Wayne M. Biocidal cleaner composition containing acid-anionic surfactant-alcohol combinations and method of using the composition
US20030133883A1 (en) * 2001-06-14 2003-07-17 Finnegan Mary Beth Oral care compositions containing grapefruit seed extract
US20030137883A1 (en) * 2002-01-21 2003-07-24 Samsung Electronics Co., Ltd. Half power supply voltage generator and semiconductor memory device using the same
US20030139382A1 (en) * 2001-09-21 2003-07-24 Alcon, Inc. Method of treating middle ear infections
US6623513B2 (en) * 2001-01-19 2003-09-23 Advanced Photodynamic Technologies, Inc. Apparatus and method of photodynamic eradication of organisms utilizing pyrrolnitrin
US6676930B2 (en) * 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6685697B1 (en) * 1998-12-04 2004-02-03 Durect Corporation Controlled release system for delivering therapeutic agents into the inner ear
US6686346B2 (en) * 1996-12-05 2004-02-03 Astra Aktiebolag Formulation
US6723709B1 (en) * 1995-08-29 2004-04-20 Fidia Advanced Biopolymers, S.R.L. Biomaterials for preventing post-surgical adhesions comprised of hyaluronic acid derivatives
US20040101506A1 (en) * 2002-11-25 2004-05-27 Fust Charles A. Composition for the prevention and treatment of inflammation of the ear
US6762160B2 (en) * 1998-11-06 2004-07-13 Universite De Montreal Composition for removing biofilms comprising a detergent and a salt forming acid
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US6851678B2 (en) * 2002-02-20 2005-02-08 Rohm Gmbh Drill for smooth- and hex-shank bits
US20050032668A1 (en) * 2003-08-04 2005-02-10 Pedersen Daniel E. Antimicrobial compositions including carboxylic acids and alkoxylated amines
US6855678B2 (en) * 2000-07-21 2005-02-15 Reginald Reith Whiteley Medical residue treatment composition comprising a lithium salt
US20050043706A1 (en) * 2003-03-14 2005-02-24 Eaton Donald J. Sinus delivery of sustained release therapeutics
US20050042240A1 (en) * 2002-01-28 2005-02-24 Utterberg David S. High viscosity antibacterials
US6869938B1 (en) * 1997-06-17 2005-03-22 Fziomed, Inc. Compositions of polyacids and polyethers and methods for their use in reducing adhesions
US20050064508A1 (en) * 2003-09-22 2005-03-24 Semzyme Peptide mediated synthesis of metallic and magnetic materials
US20050080396A1 (en) * 2003-10-03 2005-04-14 Michael Rontal Method and apparatus for the ultrasonic cleaning of biofilm coated surfaces
US6891037B1 (en) * 1997-01-24 2005-05-10 Schweiz. Serum- & Impfinstitut Bern Method for the isolation of polysaccharides
US6919348B2 (en) * 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
US20050220895A1 (en) * 2003-12-17 2005-10-06 Bucalo Louis R Use of gallium to treat inflammatory arthritis
US20050226937A1 (en) * 1998-06-01 2005-10-13 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine and adjuvants
US6962813B2 (en) * 2001-05-21 2005-11-08 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US20050282722A1 (en) * 2004-06-16 2005-12-22 Mcreynolds Kent B Two part cleaning composition
US20060003008A1 (en) * 2003-12-30 2006-01-05 Gibson John W Polymeric devices for controlled release of active agents
US6989195B2 (en) * 1997-09-09 2006-01-24 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US20060018945A1 (en) * 2003-12-04 2006-01-26 University Of Iowa Research Foundation Gallium inhibits biofilm formation
US20060035808A1 (en) * 2004-08-11 2006-02-16 Ahmed Fahim U Non-chlorinated concentrated all-in-one acid detergent and method for using the same
US20060045850A1 (en) * 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
US20060051385A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US20060106361A1 (en) * 2004-04-21 2006-05-18 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US20060210605A1 (en) * 2004-04-21 2006-09-21 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US7119217B2 (en) * 2002-09-23 2006-10-10 Genta Incorporated Tri(alkylcarboxylato)gallium (III) products and pharmaceutical compositions containing them
US7128897B2 (en) * 1999-07-06 2006-10-31 Naryx Pharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US7238363B2 (en) * 2004-04-02 2007-07-03 Baylor College Of Medicine Modification of medical prostheses
US20070207192A1 (en) * 2003-08-15 2007-09-06 Qlt Usa, Inc. Adhesive bioerodible transmucosal drug delivery system
US20080248558A1 (en) * 2004-09-10 2008-10-09 Novozymes A/S Methods For Preventing, Removing, Reducing, or Disrupting Biofilm

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002775A (en) * 1973-07-09 1977-01-11 Kabara Jon J Fatty acids and derivatives of antimicrobial agents
CA1052273A (en) * 1975-12-18 1979-04-10 Edwin B. Michaels Antimicrobial compositions
SU1128917A1 (en) 1980-12-24 1984-12-15 Кишиневский государственный медицинский институт Method of treatment of paradontosis
CA1302280C (en) 1986-04-21 1992-06-02 Jon Joseph Kabara Topical antimicrobial pharmaceutical compositions and methods
US5208257A (en) * 1986-04-21 1993-05-04 Kabara Jon J Topical antimicrobial pharmaceutical compositions and methods
US4902281A (en) * 1988-08-16 1990-02-20 Corus Medical Corporation Fibrinogen dispensing kit
SU1699430A1 (en) 1989-03-03 1991-12-23 Кишиневский государственный медицинский институт Method for treating paradontosis
CN1091315A (en) * 1992-10-08 1994-08-31 E·R·斯奎布父子公司 Fibrin sealant compositions and methods of use thereof
US5480658A (en) * 1993-07-23 1996-01-02 Melman; Steven A. Ear and skin cleanser
FR2710529A1 (en) 1993-09-29 1995-04-07 Zirinis Phedon Aqueous gel for nasal use, pellets, and process for preparing them
US5510102A (en) * 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
US5817303A (en) * 1995-05-05 1998-10-06 Protein Polymer Technologies, Inc. Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer
DK1035833T3 (en) * 1997-12-02 2006-01-09 Archimedes Dev Ltd Composition for nasal administration
US7691829B2 (en) * 1998-03-24 2010-04-06 Petito George D Composition and method for healing tissues
US20020022588A1 (en) * 1998-06-23 2002-02-21 James Wilkie Methods and compositions for sealing tissue leaks
US6706290B1 (en) * 1998-07-06 2004-03-16 Olvai E. Kajander Methods for eradication of nanobacteria
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6533749B1 (en) * 1999-09-24 2003-03-18 Medtronic Xomed, Inc. Angled rotary tissue cutting instrument with flexible inner member
EP1259113B1 (en) * 2000-02-28 2004-04-28 THE PROCTER & GAMBLE COMPANY Acidic antimicrobial compositions for treating food and food contact surfaces and methods of use thereof
US6953772B2 (en) * 2000-07-18 2005-10-11 Lopes John A Concentrated sanitizing compositions for cleaning food and food contact surfaces
US6610314B2 (en) * 2001-03-12 2003-08-26 Kimberly-Clark Worldwide, Inc. Antimicrobial formulations
US6682695B2 (en) 2001-03-23 2004-01-27 Clearant, Inc. Methods for sterilizing biological materials by multiple rates
US20030064000A1 (en) * 2001-09-24 2003-04-03 Wilson Burgess Methods of sterilizing biological mixtures using stabilizer mixtures
AU2003205227A1 (en) 2002-01-18 2003-09-02 Emory University Phthalocyanine and porphyrazine pharmaceutical compositions
US20030180181A1 (en) 2002-02-01 2003-09-25 Teri Greib Methods for sterilizing tissue
RU2228203C2 (en) 2002-04-12 2004-05-10 ООО "Наука-Сервис-Центр" Wound-healing material
WO2003088914A2 (en) 2002-04-18 2003-10-30 The University Of Iowa Research Foundation Methods of inhibiting and treating bacterial biofilms by metal chelators
EP1374856A1 (en) 2002-06-18 2004-01-02 Impetus AG Oily thixotropic nasal spray
AU2003272517A1 (en) * 2002-09-13 2004-04-30 Zicam, Llc. Compositions to reduce congestion and methods for application thereof to the nasal membrane
AU2003270504A1 (en) * 2002-09-30 2004-04-23 Bausch & Lomb Incorporated Bacterial attachment reduction to biomaterials and biomedical devices
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
GB2397067B (en) * 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
US7090882B2 (en) 2003-06-12 2006-08-15 Cargill, Incorporated Antimicrobial salt solutions for food safety applications
US20050003007A1 (en) * 2003-07-02 2005-01-06 Michele Boix Method of sterilization of polymeric microparticles
DE10347994A1 (en) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Aqueous aerosol preparation
EP1729676A1 (en) 2004-03-15 2006-12-13 Durect Corporation Pharmaceutical compositions for administration to a sinus
CN101137359B (en) * 2005-03-10 2011-01-12 3M创新有限公司 Methods of treating ear infections
WO2006099386A2 (en) 2005-03-11 2006-09-21 Massachusetts Institute Of Technology Synthesis and use of colloidal iii-v nanoparticles
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US7976873B2 (en) 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7959943B2 (en) 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US7998404B2 (en) * 2006-07-13 2011-08-16 Advanced Cardiovascular Systems, Inc. Reduced temperature sterilization of stents
WO2008097317A1 (en) 2007-02-08 2008-08-14 Medtronic Xomed, Inc. Solvating system and sealant for medical use

Patent Citations (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422186A (en) * 1962-08-06 1969-01-14 Purdue Frederick Co Methods for the removal of cerumen and the methods for the treatment of ear disease
US4323551A (en) * 1981-02-19 1982-04-06 The Procter & Gamble Company Mouthwash compositions
US5442053A (en) * 1982-09-28 1995-08-15 Fidia, S.P.A. Salts and mixtures of hyaluronic acid with pharmaceutically active substances, pharmaceutical compositions containing the same and methods for administration of such compositions
US5631241A (en) * 1983-10-10 1997-05-20 Fidia S.P.A. Pharmaceutical compositions containing hyaluronic acid fractions
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5290552A (en) * 1988-05-02 1994-03-01 Matrix Pharmaceutical, Inc./Project Hear Surgical adhesive material
US5676964A (en) * 1988-05-13 1997-10-14 Fidia, S.P.A. Crosslinked carboxy polysaccharides
US5575815A (en) * 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
US5017229A (en) * 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5145664A (en) * 1990-06-25 1992-09-08 Thompson Mckay Pharmaceuticals, Ltd. Mouthwash
US5246964A (en) * 1990-07-10 1993-09-21 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of inflammatory diseases with polyoxyethylenesorbitan mono-higher-fatty acid esters
US5326567A (en) * 1991-04-10 1994-07-05 Capelli Christopher C Antimicrobial compositions useful for medical applications
US5662913A (en) * 1991-04-10 1997-09-02 Capelli; Christopher C. Antimicrobial compositions useful for medical applications
US5229103A (en) * 1992-04-30 1993-07-20 Hydrodent Laboratories, Inc. Antiplaque mouthwash concentrate
US5644049A (en) * 1992-07-03 1997-07-01 M.U.R.S.T. Italian Ministry For Universitites And Scientific And Technology Research Biomaterial comprising hyaluronic acid and derivatives thereof in interpenetrating polymer networks (IPN)
US6248371B1 (en) * 1995-04-25 2001-06-19 Winthrop University Hospital Metal/thiol biocides
US6723709B1 (en) * 1995-08-29 2004-04-20 Fidia Advanced Biopolymers, S.R.L. Biomaterials for preventing post-surgical adhesions comprised of hyaluronic acid derivatives
US6143330A (en) * 1995-11-09 2000-11-07 Aaltonen; Antti Sakari Compositions for inhibiting dental caries and/or middle ear infections and uses thereof
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US6541460B2 (en) * 1996-08-07 2003-04-01 George D. Petito Method for use of hyaluronic acid in wound management
US5910420A (en) * 1996-08-16 1999-06-08 Orion-Yhtyma Oy Orion Diagnostica Method and test kit for pretreatment of object surfaces
US6063061A (en) * 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US6203822B1 (en) * 1996-09-03 2001-03-20 University Of Iowa Research Foundation Gallium-containing compounds for the treatment of infections caused by intracellular pathogens and pathogens causing chronic pulmonary infection
US6156792A (en) * 1996-10-01 2000-12-05 Smithkline Beecham Corporation Calcium mupirocin non-aqueous nasal spray for otitis media or for recurrent acute bacterial sinusitis
US6001870A (en) * 1996-10-01 1999-12-14 Smithkline Beecham P.L.C. Nasopharynx administration of mupirocin for prophylactic treatment of recurrent otitis media
US6224857B1 (en) * 1996-10-17 2001-05-01 Fidia, S.P.A. Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics
US5709546A (en) * 1996-11-27 1998-01-20 Waggoner; Mark B. Water sanitizing system and process
US6686346B2 (en) * 1996-12-05 2004-02-03 Astra Aktiebolag Formulation
US6891037B1 (en) * 1997-01-24 2005-05-10 Schweiz. Serum- & Impfinstitut Bern Method for the isolation of polysaccharides
US6869938B1 (en) * 1997-06-17 2005-03-22 Fziomed, Inc. Compositions of polyacids and polyethers and methods for their use in reducing adhesions
US5925334A (en) * 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US6989195B2 (en) * 1997-09-09 2006-01-24 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US5895781A (en) * 1997-12-22 1999-04-20 S. C. Johnson & Son, Inc. Cleaning compositions for ceramic and porcelain surfaces and related methods
US6395295B1 (en) * 1997-12-24 2002-05-28 Britannia Pharmaceuticals Limited Use of surface active agent for the manufacture of a medicament for treatment of disorders of the middle ear
US6013657A (en) * 1998-02-02 2000-01-11 Agis Industries Ltd. Pharmaceutical compositions containing mupirocin
US20050226937A1 (en) * 1998-06-01 2005-10-13 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine and adjuvants
US20030079758A1 (en) * 1998-06-03 2003-05-01 Siegel Phyllis B. Process and composition for removing biofilm
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6762160B2 (en) * 1998-11-06 2004-07-13 Universite De Montreal Composition for removing biofilms comprising a detergent and a salt forming acid
US6685697B1 (en) * 1998-12-04 2004-02-03 Durect Corporation Controlled release system for delivering therapeutic agents into the inner ear
US6375963B1 (en) * 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US7128897B2 (en) * 1999-07-06 2006-10-31 Naryx Pharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6284804B1 (en) * 1999-09-24 2001-09-04 Alcon Universal Ltd. Topical suspension formulations containing ciprofloxacin and dexamethasone
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6616913B1 (en) * 1999-11-28 2003-09-09 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6676930B2 (en) * 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US20020187918A1 (en) * 2000-02-01 2002-12-12 Reckitt Benckiser Inc. Hard surface cleaning compositions and method of removing stains
US6812196B2 (en) * 2000-06-05 2004-11-02 S.C. Johnson & Son, Inc. Biocidal cleaner composition containing acid-anionic surfactant-alcohol combinations and method of using the composition
US20030083219A1 (en) * 2000-06-05 2003-05-01 Rees Wayne M. Biocidal cleaner composition containing acid-anionic surfactant-alcohol combinations and method of using the composition
US6855678B2 (en) * 2000-07-21 2005-02-15 Reginald Reith Whiteley Medical residue treatment composition comprising a lithium salt
US6623513B2 (en) * 2001-01-19 2003-09-23 Advanced Photodynamic Technologies, Inc. Apparatus and method of photodynamic eradication of organisms utilizing pyrrolnitrin
US6962813B2 (en) * 2001-05-21 2005-11-08 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US20030133883A1 (en) * 2001-06-14 2003-07-17 Finnegan Mary Beth Oral care compositions containing grapefruit seed extract
US20030139382A1 (en) * 2001-09-21 2003-07-24 Alcon, Inc. Method of treating middle ear infections
US20030137883A1 (en) * 2002-01-21 2003-07-24 Samsung Electronics Co., Ltd. Half power supply voltage generator and semiconductor memory device using the same
US20050042240A1 (en) * 2002-01-28 2005-02-24 Utterberg David S. High viscosity antibacterials
US6851678B2 (en) * 2002-02-20 2005-02-08 Rohm Gmbh Drill for smooth- and hex-shank bits
US6919348B2 (en) * 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
US7119217B2 (en) * 2002-09-23 2006-10-10 Genta Incorporated Tri(alkylcarboxylato)gallium (III) products and pharmaceutical compositions containing them
US20040101506A1 (en) * 2002-11-25 2004-05-27 Fust Charles A. Composition for the prevention and treatment of inflammation of the ear
US20050043706A1 (en) * 2003-03-14 2005-02-24 Eaton Donald J. Sinus delivery of sustained release therapeutics
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20050032668A1 (en) * 2003-08-04 2005-02-10 Pedersen Daniel E. Antimicrobial compositions including carboxylic acids and alkoxylated amines
US20070207192A1 (en) * 2003-08-15 2007-09-06 Qlt Usa, Inc. Adhesive bioerodible transmucosal drug delivery system
US20050064508A1 (en) * 2003-09-22 2005-03-24 Semzyme Peptide mediated synthesis of metallic and magnetic materials
US20050080396A1 (en) * 2003-10-03 2005-04-14 Michael Rontal Method and apparatus for the ultrasonic cleaning of biofilm coated surfaces
US20060018945A1 (en) * 2003-12-04 2006-01-26 University Of Iowa Research Foundation Gallium inhibits biofilm formation
US20050220895A1 (en) * 2003-12-17 2005-10-06 Bucalo Louis R Use of gallium to treat inflammatory arthritis
US20060003008A1 (en) * 2003-12-30 2006-01-05 Gibson John W Polymeric devices for controlled release of active agents
US7238363B2 (en) * 2004-04-02 2007-07-03 Baylor College Of Medicine Modification of medical prostheses
US20060106361A1 (en) * 2004-04-21 2006-05-18 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US20060210605A1 (en) * 2004-04-21 2006-09-21 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US20050282722A1 (en) * 2004-06-16 2005-12-22 Mcreynolds Kent B Two part cleaning composition
US20060035808A1 (en) * 2004-08-11 2006-02-16 Ahmed Fahim U Non-chlorinated concentrated all-in-one acid detergent and method for using the same
US20060045850A1 (en) * 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
US20060051385A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US20080248558A1 (en) * 2004-09-10 2008-10-09 Novozymes A/S Methods For Preventing, Removing, Reducing, or Disrupting Biofilm

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110040226A1 (en) * 2008-04-24 2011-02-17 Medtronic, Inc. Cold ionizing radiation sterilization
US8653319B2 (en) 2008-04-24 2014-02-18 Medtronic, Inc. Cold ionizing radiation sterilization
US9827367B2 (en) 2008-04-29 2017-11-28 Medtronic Xomed, Inc. Surgical instrument, system, and method for frontal sinus irrigation
US20140309581A1 (en) * 2008-06-12 2014-10-16 Medtronic Xomed, Inc. Method for treating chronic wounds with an extracellular polymeric substance solvating system
US9700344B2 (en) * 2008-06-12 2017-07-11 Medtronic Xomed, Inc. Method for treating chronic wounds with an extracellular polymeric substance solvating system
US8940792B2 (en) 2008-10-06 2015-01-27 Next Science, Llc Antimicrobial composition and methods for using same
US10653133B2 (en) 2011-05-10 2020-05-19 Next Science IP Holdings Pty Ltd Antimicrobial solid and methods of making and using same
US12162785B2 (en) 2011-12-06 2024-12-10 Delta Faucet Company Ozone distribution in a faucet
US10947138B2 (en) 2011-12-06 2021-03-16 Delta Faucet Company Ozone distribution in a faucet
US9919939B2 (en) 2011-12-06 2018-03-20 Delta Faucet Company Ozone distribution in a faucet
US9452457B2 (en) * 2012-01-18 2016-09-27 Nch Corporation Composition, system, and method for treating water systems
US9707520B2 (en) 2012-01-18 2017-07-18 Nch Corporation Composition, system, and method for treating water systems
US20130239991A1 (en) * 2012-01-18 2013-09-19 Nch Corporation Composition, System, and Method for Treating Water Systems
US10021876B2 (en) 2013-05-02 2018-07-17 Next Science IP Holdings Pty Ltd High osmolarity antimicrobial composition containing one or more organic solvents
US9506016B2 (en) 2013-11-06 2016-11-29 Nch Corporation Composition and method for treating water systems
US9441190B2 (en) 2013-11-06 2016-09-13 Nch Corporation Composition and method for treating water systems
US10827750B2 (en) 2015-07-17 2020-11-10 Next Science IP Holdings Pty Ltd Antimicrobial composition having efficacy against endospores
US11458214B2 (en) 2015-12-21 2022-10-04 Delta Faucet Company Fluid delivery system including a disinfectant device
WO2021059151A1 (en) 2019-09-26 2021-04-01 3M Innovative Properties Company Oral care composition with ammonium alkyl sulfonate or carbonate components for treating caries
WO2021116873A1 (en) * 2019-12-12 2021-06-17 3M Innovative Properties Company Oral care composition with n-acetyl amino acid components for treating caries
JP2023512990A (en) * 2020-01-24 2023-03-30 スパイラル・セラピューティクス・インコーポレイテッド Devices, systems and methods for otology
US12360350B2 (en) 2020-01-24 2025-07-15 Spiral Therapeutics, Inc. Devices, systems, and methods for otology
JP7795464B2 (en) 2020-01-24 2026-01-07 スパイラル・セラピューティクス・インコーポレイテッド Devices, systems, and methods for otology
US12059430B2 (en) 2022-09-29 2024-08-13 Adora Animal Health Corporation Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
US12268708B2 (en) 2022-09-29 2025-04-08 Adora Animal Health Corporation Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
US12303528B2 (en) 2022-09-29 2025-05-20 Adora Animal Health Corporation Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions

Also Published As

Publication number Publication date
CN101443079A (en) 2009-05-27
US20090258086A1 (en) 2009-10-15
US7976875B2 (en) 2011-07-12

Similar Documents

Publication Publication Date Title
US7976875B2 (en) Biofilm extracellular polysaccharide solvating system
JP5912218B2 (en) Antibacterial extracellular polysaccharide solvation system
US7959943B2 (en) Solvating system and sealant for medical use in the middle or inner ear
US7993675B2 (en) Solvating system and sealant for medical use in the sinuses and nasal passages
CN101626762B (en) Solvating system and sealant for medical use
EP2712614B1 (en) Solvating system and sealant for medical use
HK1130717A (en) Antibacterial extracellular polysaccharide solvating system
JP2004529095A (en) Prevention of ventilator-associated pneumonia by oral administration of antibacterial IB-367 peptide
AU2013211488B2 (en) Solvating system and sealant for medical use
HRP20201673A1 (en) Local antiseptic solution for sensitive skin and mucous membrane
HK1225961A1 (en) Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
HK1162586B (en) Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
HK1216615A1 (en) Compositions and methods for the treatment or the prevention oral infections by e. coli
HK1162531B (en) Compositions and methods for the treatment or the prevention oral infections by e. coli

Legal Events

Date Code Title Description
AS Assignment

Owner name: MEDTRONIC XOMED, INC., FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MYNTTI, MATTHEW F.;REEL/FRAME:018057/0893

Effective date: 20060714

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION